CareLit Fachartikel

Pharmacologic activation of the p53 pathway using Nutlin-3 inhibits medulloblastoma cell proliferation in vitro

A Künkele, M Baumann, A Odersky, H Deubzer, O Witt, A Eggert, A Schramm, JH Schulte · Klinische Pädiatrie · 2009 · Heft 05

Dokument
1042700
CareLit-ID
Jahr
2009
Publikation
PDF
nein
Metadaten
DOI
ja
zitierfähig

Bibliografische Angaben

Zeitschrift
Klinische Pädiatrie
Autor:innen
A Künkele, M Baumann, A Odersky, H Deubzer, O Witt, A Eggert, A Schramm, JH Schulte
Ausgabe
Heft 05 / 2009
Seiten
–
Erschienen: 2009-05-11 00:00:00
ISSN
0300-8630
DOI
10.1055/s-0029-1222655

Zusammenfassung

In embryonal tumors including neuroblastoma, retinoblastoma and medulloblastoma, p53 is rarely mutated. Instead, the p53 pathway is functionally inactivated by other mechanisms such as overexpression of MDM2, which functions as an ubiquitin ligase regulating degradation of p53. Nutlin-3 is a small molecule inhibitor of the p53-MDM2 interaction. It is thereby stabilizing p53 and restoring its activity. Nutlin-3 has been proven to be effective in neuroblastoma and retinoblastoma cells in vitro. We here analysed the effects of Nutlin-3 treatment in medulloblastoma cell lines with high MDM2 expression, but not harbo…

Schlagworte

Nutlin-3 Medulloblastoma Vitro Neuroblastoma Retinoblastoma Interaction Cells Analysed Treatment Lines Models Pathway Klinische Pädiatrie